title: In a randomized controlled trial of iron fortification, anthelmintic treatment, and intermittent preventive treatment of malaria for anemia control in Ivorian children, only anthelmintic treatment shows modest benefit.
abstract: Anemia is common among children in sub-Saharan Africa and its etiology is multifactorial. Likely causes of anemia are low bioavailability of dietary iron, malaria, and helminth infection. In this study, we aimed to assess the effect of iron fortification, intermittent preventive treatment (IPT) of malaria, and anthelmintic treatment on hemoglobin concentration and anemia prevalence among school children. The study was a 6-mo, randomized, double-blind, controlled trial enrolling 591 6- to 14-y-old school children in Côte d'Ivoire using the following: 1) iron-fortified biscuits providing an additional 20 mg iron/d as electrolytic iron 4 times/wk; 2) IPT of malaria with sulfadoxine-pyrimethamine at 0 and 3 mo; and 3) anthelmintic treatment at 0 and 3 mo as the interventions. Prevalence of anemia, iron deficiency, malaria parasitemia, and helminth infection was 70.4, 9.3, 57.7, and 54.8%, respectively. Iron fortification did not improve iron status, IPT of malaria did not affect malaria burden, and neither had an impact on anemia prevalence. Anthelmintics significantly reduced the burden of helminth infections and decreased anemia prevalence (odds ratio: 0.4, 95% CI: 0.3, 0.7). The low prevalence of iron deficiency and an extended dry season that decreased malaria transmission likely reduced the potential impact of iron fortification and IPT. In this setting, anthelmintic treatment was the only intervention that modestly decreased rates of anemia.
authors.affiliation: Institute of Food, Nutrition, and Health, Swiss Federal Institute of Technology Zurich, CH-8092 Zurich, Switzerland. frohner@gainhealth
authors.forename: Fabian
authors.initials: F
authors.lastname: Rohner
authors.forename: Michael B
authors.initials: MB
authors.lastname: Zimmermann
authors.forename: Renaude J
authors.initials: RJ
authors.lastname: Amon
authors.forename: Penelope
authors.initials: P
authors.lastname: Vounatsou
authors.forename: Andreas B
authors.initials: AB
authors.lastname: Tschannen
authors.forename: Eliézer K
authors.initials: EK
authors.lastname: N'goran
authors.forename: Charlemagne
authors.initials: C
authors.lastname: Nindjin
authors.forename: Marie-Chantal
authors.initials: MC
authors.lastname: Cacou
authors.forename: Marguerite D
authors.initials: MD
authors.lastname: Té-Bonlé
authors.forename: Hortense
authors.initials: H
authors.lastname: Aka
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Sess
authors.forename: Jürg
authors.initials: J
authors.lastname: Utzinger
authors.forename: Richard F
authors.initials: RF
authors.lastname: Hurrell
mesh_terms: D000293:Adolescent; D000740:Anemia / Q000453:epidemiology / Q000517:prevention & control*; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D007560:Cote d'Ivoire / Q000453:epidemiology; D005260:Female; D006373:Helminthiasis / Q000188:drug therapy; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D014131:Trace Elements / Q000627:therapeutic use
chemical_list: D000871:Anthelmintics; D000962:Antimalarials; D014131:Trace Elements; D007501:Iron